HODL2MOON
11-20 23:15

Anthropic (ANT): After the IPO Reversal, What Would Make Me Buy?

Anthropic’s IPO was spectacular, but its first trading session also delivered an important reminder: getting allocated shares at the IPO price and buying those same shares in the open market are two completely different investments.

ANT was priced at US$83, opened on Nasdaq at US$111.50 on November 19 and briefly climbed to around US$115. However, the excitement faded quickly. It closed at US$97.17, up 17.07% from the IPO price but down 12.85% from its opening trade.

In other words, investors who received IPO allocations were still sitting on a paper gain at the close, while those who bought at the opening price were already underwater.

That is why I would not use the IPO’s headline performance alone to decide whether ANT is worth buying.

A record IPO does not automatically mean an attractive valuation

There is another important distinction in the fundraising figures.

Anthropic initially offered 980 million shares at US$83, representing approximately US$81.34 billion in gross IPO proceeds. This included shares sold by the company and existing shareholders. It is not the company’s market capitalisation, nor does the entire amount go into Anthropic’s balance sheet.

The company also arranged a separate US$26 billion strategic private placement involving investors including Google, Microsoft, Nvidia, AMD, Broadcom, Micron and TSMC Partners.

On November 20, Anthropic confirmed that the underwriters had exercised the full additional 147 million-share option. The completed public offering therefore increased to 1.127 billion shares, generating approximately US$93.5 billion in gross proceeds, including the shares sold by existing shareholders. Combined with the private placement, gross proceeds from both transactions reached approximately US$119.5 billion.

These are extraordinary fundraising figures, but the real question is what Anthropic can do with that capital.

The business opportunity is real, but the economics matter

I am not questioning the commercial potential of Claude.

Enterprise adoption, API usage and demand for AI-assisted software development are meaningful growth drivers. Anthropic’s prospectus also showed that customers generating at least US$100,000 in annual revenue increased from approximately 200 at the end of 2024 to 1,500 at the end of 2025.

That is encouraging evidence of customer expansion.

However, frontier AI is an expensive business. Compute and infrastructure expenses increased from approximately US$2.52 billion in 2024 to US$7.33 billion in 2025. That is a 190% increase.

Revenue growth alone is therefore not enough. I want to see whether gross margins improve, whether compute costs become more efficient as usage scales, and whether the company can eventually generate sustainable operating cash flow.

A company can dominate the AI conversation and still struggle to justify an extremely high market valuation if the cost of serving customers grows almost as quickly as revenue.

What would convince me to buy ANT in the open market?

I would look for four things before considering an entry.

First, price discovery needs time. I would prefer to see ANT establish a more stable trading range over several sessions rather than trying to predict its next move from the first-day opening price. The US$83 IPO price is a useful reference point, but it is not guaranteed support.

Second, I want to understand the valuation. A market capitalisation approaching trillion-dollar territory requires substantial future growth. I would compare the company’s valuation against its disclosed revenue, growth rate, margins and expected cash requirements. I would not buy simply because the share price has fallen from US$111.50.

Third, I want evidence of improving economics. Future financial reports should show whether customer growth is translating into recurring revenue, better cost efficiency and a credible path towards profitability.

Fourth, I would watch share supply and selling pressure. IPO investors, existing shareholders and employees may have different investment horizons. The timing of future share unlocks and potential selling can influence price behaviour even when the underlying business remains strong.

If these conditions improve while the valuation becomes more reasonable, I would be more comfortable considering a gradual entry rather than buying into the initial excitement.

Should I buy the listed AI partners instead?

There is another way to participate in the AI ecosystem through established companies such as Nvidia (NVDA), Microsoft (MSFT), Alphabet (GOOGL), AMD (AMD), Broadcom (AVGO) and TSMC (TSM).

However, I would not treat these stocks as substitutes for ANT.

Their investment cases are different. Nvidia benefits from selling AI computing infrastructure, Microsoft and Alphabet monetise AI through cloud and software ecosystems, while AMD and Broadcom compete in different parts of the semiconductor market.

Their participation in Anthropic’s private placement also does not mean their listed shares will automatically rise when ANT performs well.

I would assess each company according to its own earnings, valuation and capital expenditure rather than buying it simply because it has an association with Anthropic.

My position: let the numbers catch up with the excitement

Personally, I would rather miss the first 10% of a rebound than enter a newly listed stock before its valuation and trading behaviour become clearer.

Anthropic has a compelling business opportunity, but the IPO has already priced in enormous expectations. Its first-day reversal shows that even strong demand cannot eliminate valuation risk.

I would keep ANT on my watchlist, wait for its first few weeks of price discovery and pay close attention to its next financial disclosures. Meanwhile, I would continue comparing opportunities across established AI leaders such as $NVIDIA(NVDA)$  , $Microsoft(MSFT)$  , GOOGL and AMD.

The AI opportunity is still worth following. But I want to own companies because their earnings justify the price, not because their IPO attracted headlines.

For me, the best entry is not necessarily the lowest price after a sell-off. It is the price at which the business fundamentals, growth prospects and valuation finally make sense together.

Anthropic Jumps 17% in Debut: How to Position After the Reversal?
ANT opened $111.50, closed $97.17 Nov. 19: +17.07% vs $83 IPO, -12.85% from open, splitting allottees and opening buyers. Company/sellers' 980M shares were worth ~$81.34B at offer, not total fundraising or closing cap. Bulls cite Claude demand/cloud reach; bears flag compute costs, profits and volatility. Nvidia's $115.8B revenue did not halt this week's chip slide; model buzz is no financial proof. Allocation, waiting for prices to settle and owning listed cloud partners carry different risks; partner shares aren't ANT. What evidence after the reversal would justify open-market participation?
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment
1